Life sciences organizations have begun making the shift to enhance efficiency, compliance, and customer experience through digital transformation. Implementing innovative digital technologies can improve clinical trial productivity, increase research and development (R&D) throughput, accelerate drug development, and ultimately shorten time-to-market.
Yet, there are challenges that go with successfully executing a digital strategy in the Life Sciences industry.
To accelerate time-to-market, heavily-regulated life sciences organizations must digitally-enable processes, combine siloed systems, and move data to the cloud while maintaining compliance with GxP and other regulations.
Failure to meet compliance requirements as an organization digitally transforms raises risks that impact patients, and brand, and in turn can lead to financial penalties. Because of these risks, life sciences organizations especially need a full view of their product lifecycle, rather than the fragmented view offered by many systems.
Life sciences organizations are facing pressure to innovate their processes as quickly as possible. The need for accelerated transformation is necessary to accommodate the speed with which everything - patient needs and expectations, regulations, and the industry itself - is evolving.
Innovating these processes for faster results also means faster time-to-market, and more time to take advantage of the twenty-year patent window where the highest returns on investment are made.
Leading organizations are adopting low-code application development platforms for digital transformation. Low-code development accelerates the delivery of innovative business applications while maintaining security, transparency, and traceability at every step of the process.
Traditional custom development approaches or pre-built packaged solutions can have a detrimental impact on speed, performance, and scalability, and ultimately on time-to-market and patient value. This is why an agile platform approach to digital transformation is crucial and why Frost & Sullivan has called out Appian for their work in this field saying,
"The major differentiator here is that life sciences and pharmaceutical companies can maintain speed, performance, scalability, security, governance, transparency, and traceability while following GxP at every step of their accelerated digital transformation program."
Many life sciences companies still use manual, risk-ridden applications, such as Word or Excel documents that do not have real-time capabilities for the latest regulations, patient requirements, and more. With a unified platform such as Appian, customers are able to have a complete view in a single system. That system is agile enough to keep up with the latest regulation changes. That system makes sharing information between team members seamless as well.
All of this can lead to higher-quality products that come to market faster for the patients who need them.
Find out more about the Appian agile low-code platform for life sciences by visiting our Life SciencesResource Center.
"With benefits ranging from accelerated drug development and improved patient safety to increased compliance and maximized operational efficiency, Appian has clearly enhanced the value proposition for its customers of today and tomorrow." Frost & Sullivan
Learn more about why Appian's innovative low-code solution for digital transformation has been given the Frost & Sullivan 2018 Life Sciences & Pharma Product Leadership Award.
Evjatar (Evi) CohenVice President, Global Life Sciences ñ Pharma/Biotech & Med. Devices
Appian is a software company that automates business processes. The Appian AI Process Platform includes everything you need to design, automate, and optimize even the most complex processes, from start to finish. The world's most innovative organizations trust Appian to improve their workflows, unify data, and optimize operations—resulting in better growth and superior customer experiences.